pRb and p16 protein alterations in human oral tumorigenesis.
Cyclin dependent kinase inhibitor 2/multiple tumour suppressor gene 1 (CDKN2/MTS1) and retinoblastoma (Rb) tumour suppressor genes play important roles in the regulation of the cell cycle. The protein products of these genes p16INK4 (p16) and pRb, respectively, like p53 protein inhibit progression from G1 to S phase. p16 exerts its function through inhibition of CDK4-mediated phosphorylation of pRb. The pRb/p16 pathway is a critical target for molecular aberration at the G1-S checkpoint in a wide range of primary human tumours. The expression of p16 and pRb proteins was analyzed by immunohistochemistry in 35 cases of oral squamous cell carcinomas (SCCs), 22 cases of premalignant oral lesions and 30 normal oral tissues. Lack of pRb expression was observed in 23/35 (66%) oral SCCs and 14/22 (64%) premalignant lesions. Lack of p16 expression was observed in 22/35 (63%) oral SCCs and 13/22 (59%) premalignant lesions. Weak p16 and pRb immunoreactivities were observed in normal oral mucosal epithelium. The status of p16 and pRb was correlated with clinicopathological characteristics of the patients. Alteration in p16 expression showed significant correlation with tumour staging and progression (P = 0.024). Alteration in pRb/p16 expression correlated with heavy consumption of betel and tobacco. Our results suggest that alterations in the p16/pRb pathway are early events in oral tumorigenesis and may be involved in the development of betel- and tobacco-related oral malignancies.
Pande
P
P
Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Mathur
M
M
Shukla
N K
NK
Ralhan
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001114:Areca; D002294:Carcinoma, Squamous Cell / Q000209:etiology / Q000378:metabolism*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015870:Gene Expression; D016161:Genes, Retinoblastoma / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D007972:Leukoplakia, Oral / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000209:etiology / Q000378:metabolism*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D014030:Tobacco, Smokeless / Q000009:adverse effects
D019941:Cyclin-Dependent Kinase Inhibitor p16